Trial Profile
A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation +/- Taxotere (Docetaxel) for Non-metastatic Prostate Cancer Patients With a Rising PSA
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Aug 2023
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Bicalutamide
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 12 Aug 2021 Planned End Date changed from 1 Dec 2023 to 1 Apr 2023.
- 12 Aug 2021 Planned primary completion date changed from 1 Dec 2023 to 1 Apr 2023.
- 06 Aug 2018 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.